Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors
Grailer, J. et al., Promega Corporation
AACR 2020 Abstract #944A major challenge in the development of antibody-based biologic drugs is access to quantitative and reproducible functional bioassays. In contrast to the cumbersome, variable methods currently used that rely on primary cells, we have developed a portfolio of functional cell-based reporter bioassays to quantitatively measure the potency of biologic drugs designed to target immune checkpoint receptors including co-inhibitory (e.g., PD-1, CTLA-4, LAG-3, SIRPα) and co-stimulatory (e.g., 4-1BB, GITR, ICOS) receptors. These bioassays consist of stable cell lines that express luciferase under the precise control of receptor-mediated intracellular signals. Here we describe the application of these MOA-based bioassays for biologics drug discovery, development, potency and stability studies.
Get This Poster PDF